<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02108392</url>
  </required_header>
  <id_info>
    <org_study_id>pending</org_study_id>
    <nct_id>NCT02108392</nct_id>
  </id_info>
  <brief_title>Characterization of Pseudoxanthoma Elasticum</brief_title>
  <official_title>Characterization of Patients With Pseudoxanthoma Elasticum</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bonn</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bonn</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pseudoxanthoma elasticum (PXE) is a rare multisystem disorder of autosomal recessive
      inheritance (OMIM# 264800) and an estimated prevalence between 1:25.000 and 1:100.000. PXE is
      characterized by calcification and fragmentation of connective tissue rich in elastic fibers.
      Due to its high content of elastic fibers, Bruch Membrane in eyes of patients affected by PXE
      becomes thickened and calcified. The ocular phenotype is characterized by angioid streaks and
      peau d'orange but also choroidal neovascularizations and chorioretinal atrophy thereby in
      part mimicking the phenotype of age-related macular degeneration. The disease is due to
      mutations of the ABCC6-gene coding for a transmembrane protein which is mainly expressed in
      the liver and kidney. It is hypothesized that ABCC6 is involved in the excretion of a yet
      unknown factor from the liver which inhibits systemic calcification. In animal models several
      candidates for this factor have been identified but direct evidence for such a factor in
      patients with PXE is still missing. The primary purpose of this study is to further
      investigate the ocular phenotype of patients with PXE using multimodal imaging and functional
      testing to delineate the impact of Bruch membrane pathology on the eye. Furthermore, possible
      systemic anti-calcification factors, as well as associations with the vascular alterations
      are investigated to gain more insights into the pathogenesis of PXE..
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular phenotype</measure>
    <time_frame>patients will be followed longitudinally with an expected 1-year average interval between visits</time_frame>
    <description>Patients are investigated using a multimodal imaging approach and visual function testing.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biomarkers in PXE</measure>
    <time_frame>1 day (first visit)</time_frame>
    <description>Potential systemic biomarkers are investigated by collecting blood samples of PXE patients</description>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Pseudoxanthoma Elasticum</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Pseudoxanthoma elasticum
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Pseudoxanthoma elastcium based on histopathologic and/or genetic testing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Charbel Issa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Ophthalmology, University of Bonn</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Ophthalmology, University of Bonn</name>
      <address>
        <city>Bonn</city>
        <state>NRW</state>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.augenklinik.uni-bonn.de/</url>
    <description>Webpage of the University Eye Hospital of Bonn</description>
  </link>
  <reference>
    <citation>Gliem M, Zaeytijd JD, Finger RP, Holz FG, Leroy BP, Charbel Issa P. An update on the ocular phenotype in patients with pseudoxanthoma elasticum. Front Genet. 2013 Apr 4;4:14. doi: 10.3389/fgene.2013.00014. eCollection 2013.</citation>
    <PMID>23577018</PMID>
  </reference>
  <reference>
    <citation>Finger RP, Fenwick E, Marella M, Charbel Issa P, Scholl HP, Holz FG, Lamoureux EL. The relative impact of vision impairment and cardiovascular disease on quality of life: the example of pseudoxanthoma elasticum. Health Qual Life Outcomes. 2011 Dec 12;9:113. doi: 10.1186/1477-7525-9-113.</citation>
    <PMID>22152229</PMID>
  </reference>
  <reference>
    <citation>Charbel Issa P, Finger RP, Götting C, Hendig D, Holz FG, Scholl HP. Centrifugal fundus abnormalities in pseudoxanthoma elasticum. Ophthalmology. 2010 Jul;117(7):1406-14. doi: 10.1016/j.ophtha.2009.11.008. Epub 2010 Mar 1.</citation>
    <PMID>20189652</PMID>
  </reference>
  <reference>
    <citation>Finger RP, Charbel Issa P, Ladewig M, Götting C, Holz FG, Scholl HP. Fundus autofluorescence in Pseudoxanthoma elasticum. Retina. 2009 Nov-Dec;29(10):1496-505. doi: 10.1097/IAE.0b013e3181aade47.</citation>
    <PMID>19823106</PMID>
  </reference>
  <reference>
    <citation>Charbel Issa P, Finger RP, Holz FG, Scholl HP. Multimodal imaging including spectral domain OCT and confocal near infrared reflectance for characterization of outer retinal pathology in pseudoxanthoma elasticum. Invest Ophthalmol Vis Sci. 2009 Dec;50(12):5913-8. doi: 10.1167/iovs.09-3541. Epub 2009 Jun 24.</citation>
    <PMID>19553619</PMID>
  </reference>
  <reference>
    <citation>Gliem M, Finger RP, Fimmers R, Brinkmann CK, Holz FG, Charbel Issa P. Treatment of choroidal neovascularization due to angioid streaks: a comprehensive review. Retina. 2013 Jul-Aug;33(7):1300-14. doi: 10.1097/IAE.0b013e3182914d2b. Review.</citation>
    <PMID>23719398</PMID>
  </reference>
  <reference>
    <citation>Gliem M, Fimmers R, Müller PL, Brinkmann CK, Finger RP, Hendig D, Holz FG, Charbel Issa P. Choroidal changes associated with Bruch membrane pathology in pseudoxanthoma elasticum. Am J Ophthalmol. 2014 Jul;158(1):198-207.e3. doi: 10.1016/j.ajo.2014.04.005. Epub 2014 Apr 13.</citation>
    <PMID>24727260</PMID>
  </reference>
  <reference>
    <citation>Charbel Issa P, Gliem M, Holz FG, Knabbe C, Hendig D. [Pseudodominant inheritance of pseudoxanthoma elasticum]. Ophthalmologe. 2015 Aug;112(8):686-90. doi: 10.1007/s00347-014-3231-9. Review. German.</citation>
    <PMID>25735631</PMID>
  </reference>
  <reference>
    <citation>Gliem M, Hendig D, Finger RP, Holz FG, Charbel Issa P. Reticular pseudodrusen associated with a diseased bruch membrane in pseudoxanthoma elasticum. JAMA Ophthalmol. 2015 May;133(5):581-8. doi: 10.1001/jamaophthalmol.2015.117. Erratum in: JAMA Ophthalmol. 2015 May;133(5):621.</citation>
    <PMID>25764262</PMID>
  </reference>
  <reference>
    <citation>Gliem M, Müller PL, Birtel J, Hendig D, Holz FG, Charbel Issa P. Frequency, Phenotypic Characteristics and Progression of Atrophy Associated With a Diseased Bruch's Membrane in Pseudoxanthoma Elasticum. Invest Ophthalmol Vis Sci. 2016 Jun 1;57(7):3323-30. doi: 10.1167/iovs.16-19388.</citation>
    <PMID>27367499</PMID>
  </reference>
  <reference>
    <citation>Gliem M, Müller PL, Birtel J, McGuinness MB, Finger RP, Herrmann P, Hendig D, Holz FG, Charbel Issa P. Quantitative Fundus Autofluorescence in Pseudoxanthoma Elasticum. Invest Ophthalmol Vis Sci. 2017 Dec 1;58(14):6159-6165. doi: 10.1167/iovs.17-22007.</citation>
    <PMID>29214314</PMID>
  </reference>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>April 1, 2014</study_first_submitted>
  <study_first_submitted_qc>April 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2014</study_first_posted>
  <last_update_submitted>June 18, 2018</last_update_submitted>
  <last_update_submitted_qc>June 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Bonn</investigator_affiliation>
    <investigator_full_name>Peter Charbel Issa</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>PXE</keyword>
  <keyword>phenotype</keyword>
  <keyword>eye</keyword>
  <keyword>biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pseudoxanthoma Elasticum</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

